Adaptive Biotechnologies Corp (NASDAQ: ADPT) is a biotechnology company that focuses on the development of immune-driven medicine. The company leverages its proprietary immune medicine platform to discover, develop, and commercialize products that aim to diagnose and treat diseases. Despite its innovative approach, ADPT faces competition from other biotech firms in the rapidly evolving healthcare sector.
On March 18, 2026, Julie Rubinstein, President and COO of ADPT, sold 19,060 shares at $13.18 each. This transaction is part of a series of sales Rubinstein executed in March. Earlier, on March 11th, she sold 141,583 shares at $13.29, totaling approximately $1.88 million. These sales reduced her holdings by 21.51%, leaving her with 516,610 shares valued at around $6.87 million.
Rubinstein's transactions continued with the sale of 19,060 shares on March 13th at $12.96 each, totaling $247,017. Additionally, on March 9th, she sold 30,941 shares at $14.79 each, amounting to $457,617.39. These sales were disclosed in a legal filing with the SEC, providing transparency to investors and stakeholders.
Despite a negative price-to-earnings (P/E) ratio of -34.18, ADPT's price-to-sales ratio is about 7.38, indicating investor willingness to pay $7.38 for every dollar of sales. The enterprise value to sales ratio is approximately 8.14, reflecting the company's valuation relative to its sales. However, the enterprise value to operating cash flow ratio is significantly negative at around -49.04, highlighting challenges in generating cash flow from operations.
The company's earnings yield is negative at approximately -2.93%, further emphasizing profitability issues. However, ADPT maintains a debt-to-equity ratio of 1.28, suggesting a moderate level of debt compared to its equity. The current ratio of 3.34 indicates a strong ability to cover short-term liabilities with short-term assets, providing some financial stability amidst its profitability challenges.
